Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Clinical trial NCT05586100 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05586100
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

Start date: 2022-10-13
Primary completion: 2025-04-28
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.